Giovanni Magnaghi assumes the role of CEO at Zambon
Zambon, a leading pharmaceutical company, has announced the appointment of Giovanni Magnaghi as its new CEO. The decision was made by the board of directors in order to lead the company in implementing its strategic plan for the future.
Magnaghi, who has been with Zambon since 2018 as the group’s chief financial officer, has played a crucial role in achieving not only financial goals but also in the establishment and development of Zambon Biotech. Prior to joining Zambon, he had worked at renowned companies such as Gilead Sciences, Gillette Group, Bausch & Lomb, and Henry Schein.
Elena Zambon, president of the Zambon Group, expressed her confidence in Magnaghi’s abilities and leadership. She believes that together with the executive management committee, he will be able to define and implement upcoming launches in both existing markets and the United States. Furthermore, Magnaghi is expected to accelerate the consolidation and growth of Zambon’s proprietary brands.
“I am extremely pleased with the decision of the board,” said Giovanni Magnaghi. “I am well aware of the responsibility that comes with leading a company that has been in existence for 118 years and has an exciting path of growth ahead.”
The board of directors also expressed their gratitude to Ilaria Villa, who had previously served as CEO of Zambon. Under her leadership, the company underwent a transformation and remained committed to its core values throughout.
The appointment of Giovanni Magnaghi as CEO marks an important milestone for Zambon. With his extensive experience in the pharmaceutical industry and his proven track record of success, he is expected to lead the company towards further growth and success.
Zambon, founded in 1906, has a strong presence in Italy and other countries around the world. The company is known for its focus on research and development, as well as its commitment to improving the health and well-being of patients.
As Zambon embarks on this new chapter under the leadership of Giovanni Magnaghi, it is sure to continue its legacy of innovation and excellence in the pharmaceutical industry.